A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

Inclusion Criteria Required immediately prior to study entry: A minimum of 2 and a maximum of 12 months of AZT therapy at 500-600 mg/day (does not apply to the pilot group patients receiving vaccine only and to patients with CD4 counts of 50-199 cells/mm3). Concurrent Medication: Allowed: PCP prophylaxis. Rifabutin and clarithromycin (in patients with CD4 counts of 50-199 cells/mm3 only). Short-term nonsteroidal anti-inflammatory therapy for acute conditions. Short intermittent cycles of acyclovir. Patients must have: HIV infection, with CD4 count of 50-500 cells/mm3. No active opportunistic infection (patients with CD4 counts of 50-199 cells/mm3 may have a history of an opportunistic infection). Consent of parent, guardian, or person with power of attorney, if less than 18 years of age. B-cell lines established in order to be vaccinated. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known or suspected allergies to any vaccine components. Concurrent Medication: Excluded: Agents with immunosuppressive activity. Antiretroviral therapies other than AZT (except in patients with CD4 counts of 50-199 cells/mm3). Interferon. Parenteral therapies (including SC allergy medications and chemotherapy for Kaposi's sarcoma). Steroids. Hematopoietins. Prior Medication: Excluded within 12 weeks prior to study entry: Agents with immunosuppressive activity. Antiretroviral therapies other than AZT (except in patients with CD4 counts of 50-349 cells/mm3). Interferon. Parenteral therapies (including SC allergy medications and chemotherapy for Kaposi's sarcoma). Steroids. Hematopoietins. Active drug abuse.